Entero Therapeutics, Inc. (NASDAQ:GRDX) Sees Large Decline in Short Interest

Entero Therapeutics, Inc. (NASDAQ:GRDX) saw a significant decrease in short interest in October. As of October 30th, there was short interest totaling 30,489 shares, a decrease of 69.3% from the October 15th total of 99,241 shares. Based on an average daily volume of 116,642 shares, the short-interest ratio is presently 0.3 days. Approximately 0.4% of the shares of the stock are sold short.

Entero Therapeutics Trading Down 29.6%

Shares of NASDAQ:GRDX traded down $1.61 on Friday, hitting $3.81. The company had a trading volume of 382,897 shares, compared to its average volume of 116,103. The company has a market cap of $27.19 million, a PE ratio of -2.00 and a beta of 1.67. Entero Therapeutics has a 52-week low of $1.87 and a 52-week high of $6.93. The business has a 50 day moving average of $4.25 and a 200 day moving average of $3.62.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded shares of Entero Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, November 7th.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing orally administered therapies for gastrointestinal diseases. The company’s research programs are designed to address conditions involving intestinal inflammation, gluten intolerance and digestive enzyme deficiencies. Its pipeline has included latiglutenase, an oral enzyme therapy being developed for celiac disease, as well as niclosamide-based therapies for inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease.